---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pathophysiology"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Pathophysiology. Topics: NPC1 and NPC2 proteins in lysosomal cholesterol trafficking, Functions of the NPC1 and NPC2 proteins, Molecular pathogenesis: loss of function and lysosomal lipid accumulation, Cellular hallmark and its reversal by 2-hydroxypropyl-beta-cyclodextrin in cultured cells, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/pathophysiology"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### NPC1 and NPC2 proteins in lysosomal cholesterol trafficking

> “These proteins work sequentially to facilitate the bidirectional cellular trafficking of cholesterol and other lipids from the lysosome to the endoplasmic reticulum”
> “Variants that cause disease in either gene lead to tissue accumulation of multiple lipids”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.4-2"></a>

### Functions of the NPC1 and NPC2 proteins

> “NPC1 is an integral membrane protein that facilitates the transport of cholesterol across the endolysosomal membrane, and NPC2 is a non-enzymatic soluble lysosomal protein that likely transports cholesterol from the lysosomal lumen to NPC1”
> “Impaired function of either NPC1 or NPC2 leads to an endolysosomal accumulation of cholesterol and glycosphingolipids”

Source: [Bianconi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535124/)

<a id="topic-2.2.1.4-3"></a>

### Molecular pathogenesis: loss of function and lysosomal lipid accumulation

> “Pathogenic variants described throughout NPC1 and NPC2 lead to either dysfunction or complete loss of the proteins NPC1 or NPC2, the deficiency of which leads to accumulation in the lysosomes of multiple lipid cargoes including unesterified cholesterol, glucosylceramide, and gangliosides.”
> “The consequent lysosomal dysfunction leads to a cascade of downstream effects, including an inflammatory response and triggering of apoptosis.”
> “Mechanism of disease causation. Loss of function; supported by in vitro studies”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.4-4"></a>

### Cellular hallmark and its reversal by 2-hydroxypropyl-beta-cyclodextrin in cultured cells

> “In Niemann-Pick C disease cells (either NPC1 or NPC2), the cholesterol does not exit the endocytic pathway but accumulates within lysosomes.”
> “This anomaly constitutes the cellular hallmark of the disease.”
> “Very recently, it was further shown that the block in cholesterol delivery to the ER can also be overcome by 2-hydroxypropyl-beta-cyclodextrin”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.4-5"></a>

### Neuronal pathogenesis

> “The pathogenesis of the neuronal dysfunction appears by far more complex, since brain cholesterol is synthesized locally, mostly by oligodendroglial cells and to a lesser extent by astrocytes and neurons.”
> “Nevertheless, since abnormal filipin staining of neurons is also observed in a wide spectrum of other lysosomal storage disorders [discussed in 63], the exact participation of cellular cholesterol transport abnormalities in the pathophysiology of the neurodegenerative NP-C disease remains elusive.”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.4-6"></a>

### Genotype and early-onset disease

> “Premature-termination-codon variants, variants involving the sterol-sensing domain, and p.Ala1054Thr in the cysteine-rich luminal loop of NPC1 are associated with early-infantile NPC”
> “No individuals with p.Ile1061Thr had early-infantile NPC in an international study that included the Hispanic population in the upper Rio Grande Valley of the southwestern United States, as well as the United Kingdom and France”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.4-7"></a>

### Cholesterol trafficking defect and genotype: Oregon Medicaid drug evaluation

> “Presence of stop mutations on both alleles is associated with severe disease progression and early onset, while other genotype/phenotype relationships have not been consistently described.”
> “These mutations result in abnormal cholesterol trafficking and esterification.”
> “Toxic cholesterol accumulates in the lysosome and results in cell damage.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
